InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (5 ops.)
Insider track record
CEODisclosed buys
3
Disclosed sells
5
T+90 hit rate
56%
T+90 mean return
+28.5%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by ABALLI JOHN, Chief Executive Officer. Officer active across 1 company, notably EXAGEN INC.. Cumulatively, 14 filings have been published. Split: 3 buys · 5 sells. Total volume traded: €1.1m. Activity tracked since 16 October 2022. The latest transaction was disclosed on 24 February 2026 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations14 total
11,430 shares@ US$3.614.9% of flowCommon StockSEC:0001843113-26-000002
11,430 shares@ US$3.610.040% mcap4.9% of flowCommon StockSEC:0001843113-26-000002:0
31,787 shares@ US$11.81610.37% mcap45.1% of flowCommon StockSEC:0001843113-25-000003:0
31,787 shares@ US$11.816145.1% of flowCommon StockSEC:0001843113-25-000003
8,621 shares@ US$2.4651.7% of flowCommon StockSEC:0001274737-25-000013:0
112,500 shares0Common StockSEC:0001274737-25-000010:0
24,305 shares@ US$2.815.4% of flowCommon StockSEC:0001274737-24-000094:0
Ideal exit: 11 Aug 2025 (T+270)
40,401 shares@ US$1.926.0% of flowCommon StockSEC:0001274737-24-000052:0
Ideal exit: 10 Feb 2025 (T+270)
9,804 shares@ US$1.911.5% of flowCommon StockSEC:0001274737-24-000015:0
175,000 shares0Common StockSEC:0001274737-24-000012:0
33,819 shares@ US$1.74514.7% of flowCommon StockSEC:0001274737-23-000094:0
9,803 shares@ US$2.1421.6% of flowCommon StockSEC:0001274737-23-000091:0
90,000 shares@ US$2.6819.3% of flowCommon StockSEC:0001274737-22-000083:0
Ideal exit: 4 Sept 2023 (T+270)
350,000 shares0Restricted Stock UnitsSEC:0001843113-22-000010:0
14 of 14 declarations
About ABALLI JOHN
John Aballi is the President and Chief Executive Officer of EXAGEN INC. He leads the company in developing diagnostic solutions, aiming to enhance healthcare. His expertise in business and technology is an asset for EXAGEN.
